Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in generalized myasthenia gravis
NCT05067348Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Jul 2022
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in myasthenia gravis (MG), sponsored by Tangdu Hospital. Started Jul 2022; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05067348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05067348.